• Elotuzumab comes in a powder form which should be mixed with sterile water. It should be given intravenously or directly into the vein by a health care provider in a hospital setting.
• Two doses of dexamethasone – a 28 mg dose given by mouth 3 to 24 hours before and an 8 mg dose given intravenously 45 to 90 minutes – should be administered before elotuzumab injection is given.
• When elotuzumab is not given on day 8 and day 22 of the 3rd, and the subsequent cycles, the dose of dexamethasone tablet should be increased to 40 mg instead of 28 mg.
• Diphenhydramine should be given as a 25 - 50 mg tablet or injection into the vein to prevent any infusion-related allergies.
• Ranitidine is given either as a 50 mg injection into the vein or a 150 mg tablet by mouth along with paracetamol 650 mg to 1000 mg tablet to be taken by mouth.
• Mix the vial contents in an environment free from contamination and diluted with 0.9% sodium chloride or 5% dextrose solution. The diluted mixture should be used within 24 hours of the diluted or reconstituted procedure.
Lenalidomide is also given to the patient as a dose of 25 mg by mouth from day 1 to day 21 of every 28-day cycle of elotuzumab treatment.
Patients should be pre-medicated with the following medications-
• Dexamethasone
• Diphenhydramine
• Ranitidine
• Acetaminophen or paracetamol
The dose of elotuzumab is adjusted based on the infusion-related side effects and the treatment with elotuzumab can be permanently stopped if the infusion-related side effects are severe.
• Allergic to elotuzumab
• Pregnancy and breastfeeding
• Children under the age of 18 years
• Severe liver disease
• Two doses of dexamethasone – a 28 mg dose given by mouth 3 to 24 hours before and an 8 mg dose given intravenously 45 to 90 minutes – should be administered before elotuzumab injection is given.
• When elotuzumab is not given on day 8 and day 22 of the 3rd, and the subsequent cycles, the dose of dexamethasone tablet should be increased to 40 mg instead of 28 mg.
• Diphenhydramine should be given as a 25 - 50 mg tablet or injection into the vein to prevent any infusion-related allergies.
• Ranitidine is given either as a 50 mg injection into the vein or a 150 mg tablet by mouth along with paracetamol 650 mg to 1000 mg tablet to be taken by mouth.
• Mix the vial contents in an environment free from contamination and diluted with 0.9% sodium chloride or 5% dextrose solution. The diluted mixture should be used within 24 hours of the diluted or reconstituted procedure.
Dosage & When it is to be taken
The dose of elotuzumab is calculated based on the individual patient’s body weight and the recommended dose is 10 mg/kg body weight given every week during the first two cycles and for every two weeks for subsequent cycles.Lenalidomide is also given to the patient as a dose of 25 mg by mouth from day 1 to day 21 of every 28-day cycle of elotuzumab treatment.
Patients should be pre-medicated with the following medications-
• Dexamethasone
• Diphenhydramine
• Ranitidine
• Acetaminophen or paracetamol
The dose of elotuzumab is adjusted based on the infusion-related side effects and the treatment with elotuzumab can be permanently stopped if the infusion-related side effects are severe.
When it is not to be taken (Contraindications)
Elotuzumab should not be used in patients-• Allergic to elotuzumab
• Pregnancy and breastfeeding
• Children under the age of 18 years
• Severe liver disease
